CTOs on the Move

Seismic Therapeutic

www.seismictx.com

 
We are The Machine Learning Immunology Company. Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. Using our IMPACT™ platform, we are fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies for patients. Seismic Therapeutic has an emerging pipeline of novel approaches to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.seismictx.com
  • 238 Main Street 5th Floor
    Cambridge, MA USA 02142
  • Phone: 617.294.9424

Executives

Name Title Contact Details

Similar Companies

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.

Concept Medical

Concept Medical Inc. (CMI) is establishment of USA with the vision of `Inspiring Innovation`. CMI was founded in year 2008, having the mission of `converting concepts into reality` in the field of drug delivering medical devices industry.

Proteus Biomedical

Proteus Biomedical is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicuRx Pharmaceuticals

MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.

MBX Biosciences

MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.